COCP - CONSENSUS CO - Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (COCP) relies on a highly scalable synthesis technology for affordable medicines, enabling the deployment of mass global production. Business risks are mitigated by a broad pipeline of developments targeting noroviruses, COVID-19, and influenza. The current metric stands at 8.01. This price chart, which assists in the asset's baseline valuation, complements data on the systematic progression of R&D projects through clinical trial stages and the preparation of regulatory reports.

Investors use this indicator to determine an asset's fair value by comparing the current price with the expectations of the professional community. The calculation is based on the average target prices from investment firms, and the market consensus target for Cocrystal Pharma, Inc. (COCP) reflects a growth potential that, for the biotech sector, depends on clinical trial success rather than macroeconomic cycles.